Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera - Summary - MDSpire

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

  • By

  • A. Angona

  • B. Cuevas

  • M. Pérez-Encinas

  • F. Ferrer-Marin

  • A. Senín

  • E. Arellano-Rodrigo

  • J. C. Hernández-Boluda

  • M. I. Mata Vázquez

  • G. Caballero-Navarro

  • M. T. Gómez-Casares

  • E. Magro

  • G. Carreño-Tarragona

  • M. A. Cortés-Vázquez

  • R. Pérez López

  • V. García-Gutiérrez

  • M. S. Noya-Pereira

  • J. M. Alonso-Dominguez

  • C. Sierra- Aisa

  • L. Fox

  • C. García Hernández

  • J. M. Guerra

  • E. Cerezo

  • M. Gasior

  • M. Santaliestra

  • I. Díez

  • M. V. Cuevas

  • L. Sanz

  • I. Pastor

  • R. Stuckey

  • P. Vélez

  • C. Auría-Caballero

  • A. Alvarez-Larrán

  • May 7, 2026

  • 0 min

Share

Objective:

To assess the prognostic impact of arterial and venous thrombotic events on survival, disease progression, and risk of second cancer in patients with essential thrombocythemia (ET) and polycythemia vera (PV), focusing on the implications for clinical management.

Key Findings:
  • Arterial thrombosis (AT) significantly associated with lower survival rates in both ET and PV patients, indicating a critical area for clinical intervention.
  • No significant association found between venous thrombosis (VT) and survival, suggesting different clinical implications for AT and VT.
  • Development of second cancers (SC) was not significantly associated with thrombotic events in ET, but AT indicated a trend towards increased risk in PV, warranting further investigation.
Interpretation:

AT after diagnosis correlates with increased mortality and may indicate a more aggressive disease biology in MPN patients, while VT does not show a similar impact on survival, highlighting the need for targeted prevention strategies.

Limitations:
  • The study did not find significant associations between thrombosis and progression to myelofibrosis, which may limit the understanding of disease progression.
  • Low incidence of splanchnic thrombosis limited further exploration of its impact on survival, suggesting a need for larger studies.
Conclusion:

Preventing arterial thrombosis is crucial in managing MPNs due to its association with worse outcomes. Further research is needed to explore the biological mechanisms behind these associations and to develop targeted therapies.

Original Source(s)

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

  • by A. Angona, B. Cuevas, M. Pérez-Encinas, F. Ferrer-Marin, A. Senín, E. Arellano-Rodrigo, J. C. Hernández-Boluda, M. I. Mata Vázquez, G. Caballero-Navarro, M. T. Gómez-Casares, E. Magro, G. Carreño-Tarragona, M. A. Cortés-Vázquez, R. Pérez López, V. García-Gutiérrez, M. S. Noya-Pereira, J. M. Alonso-Dominguez, C. Sierra- Aisa, L. Fox, C. García Hernández, J. M. Guerra, E. Cerezo, M. Gasior, M. Santaliestra, I. Díez, M. V. Cuevas, L. Sanz, I. Pastor, R. Stuckey, P. Vélez, C. Auría-Caballero, A. Alvarez-Larrán

  • May 7, 2026

Related Content